Anton Pozniak

TL;DR: The 2008 BHIVA Guidelines have been updated to incorporate all the new relevant information since the last iteration and all the peer-reviewed publications and important, potentially treatment-changing abstracts from the last 2 years have been reviewed.

TL;DR: These elite neutralizers provide promising starting material for the isolation of broadly neutralizing monoclonal antibodies to assist in HIV-1 vaccine design.

TL;DR: Renal and bone effects were significantly reduced in patients given E/C/F/tenofovir alafenamide or E-C-F-tenofavir disoproxil fumarate and the main outcomes were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by the US Food and Drug Adminstration snapshot algorithm and pre-specified renal and bone endpoints at 48 weeks.

TL;DR: Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravIR in this treatment-experienced patient group.

TL;DR: Results are reported from a study comparing initial HIV-1 treatment with bictegravir with a novel INSTI with a high in-vitro barrier to resistance and low potential as a perpetrator or victim of clinically relevant drug interactions, showing non-inferiority of the bictricitabine regimen to the dolutegravIR regimen.